Just Published: "Netherlands Pharmaceuticals & Healthcare Report Q2 2015"

Although the Dutch economy is expected to grow above the eurozone average over 2015 and 2016, the government will most likely continue to target the healthcare sector, resulting in further drug price cuts as it responds to rising healthcare costs from the demands of an increasing aging population. We uphold our view that the Netherlands ' generic and patented drug manufactures will continue to face difficult challenges and that overall market growth will be marginal over the coming years.

Headline Expenditure Projections

* Pharmaceuticals: EUR5.92bn (USD7.93bn) in 2014 to EUR5.85bn (USD7.31bn) in 2015; -1.2% in local currency terms and -7.9% in US dollar terms.
* Healthcare: EUR71.31bn (USD95.56bn) in 2014 to EUR72.55bn (USD90.69bn) in 2015; 1.7% in local currency terms and -5.1% in US dollar terms.

Full Report Details at
- http://www.fastmr.com/prod/953250_netherlands_pharmaceuticals_healthcare_report_q2.aspx?afid=301

Risk/Reward Index

The Netherlands continues to rank in the lower half of BMI's Risk/Reward Index (RRI) for the 15 key Western European markets, ranking 11th in our ratings for Q215. The country has moved up a position from last quarter. At 65.9, its overall RRI score remains only slightly below the regional average of 67.4. While the country offers drugmakers a relatively low-risk operating environment, poor market prospects - due to pressures on pricing and reimbursement and the market's maturity - will continue to weigh down the country's overall standing.

Key Trends And Developments

December 2014

Dutch electronics company Philips has entered an agreement to acquire US-based medical device maker Volcano for USD1.2bn or USD18 a share, including debt. The offer represents a 57% premium on Volcano's closing price of USD11.49 on December 16. The acquisition aims to tap into the ageing population's need for more complex treatments, and will bolster Philips' line-up of medical imaging devices. The deal is expected to add to Philips' earnings per share by 2017, according to the company's statement. Volcano manufactures imaging catheters, which are used in...

The Netherlands Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Netherlands Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Netherlands pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Netherlands, to test other views - a key input for successful budgeting and strategic business planning in the Dutch pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Nigeria Pharmaceuticals & Healthcare Report Q2 2015
- Mexico Pharmaceuticals & Healthcare Report Q2 2015
- Thailand Pharmaceuticals & Healthcare Report Q2 2015
- Croatia Pharmaceuticals & Healthcare Report Q2 2015
- Kenya Pharmaceuticals & Healthcare Report Q2 2015